ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - Γαστροεντερικά ορμονικά στεροειδή - Άλλοι αντινεοπλασματικοί παράγοντες, αναστολείς πρωτεϊνικής κινάσης - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
imatinib koanaa
koanaa healthcare gmbh - το imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - Αντινεοπλασματικοί παράγοντες - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. Ασθενείς χαμηλού ή πολύ χαμηλού κινδύνου της υποτροπής δεν θα πρέπει να λαμβάνουν επικουρική θεραπεία. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. Εκτός από τη νεοδιαγνωσθείσα ΧΜΛ σε χρόνια φάση, δεν υπάρχουν ελεγχόμενες μελέτες που να καταδεικνύουν κλινικό όφελος ή αυξημένη επιβίωση για αυτές τις ασθένειες.
aagent, 50 mg/ml, solution for injection for calves and piglets up to one month old
qj01gb03 - granted - fatro spa italy - n. a. chance trading co
amoxy-kel 15 150 mg amoxicillin/ml suspension for injection
qj01ca04 - granted - kela n.v. - n. a. chance trading co
bilosin 200 mg/ml solution for injection for pigs
qj01fa90 - granted - bimeda animal health limited - panchris feeds (veterinary) ltd
coenzile 10,000µg/20ml, lyophilised, and solvent for solution for injection for cattle, horses, swine, dogs and cats
qb03ba04 - granted - fatro spa italy - n. a. chance trading co
fatrocortin 1 mg/ml solution for injection for cattle, swine, horses, dogs and cats
qh02ab02 - granted - fatro spa italy - n. a. chance trading co
metabolase, solution for injection for cattle, other large ruminants, horses, swine, sheep, goats, rabbits, dogs and cats.
qv03ax - granted - fatro spa italy - n. a. chance trading co
tetroxy la injection 200mg/ml solution for injection
qj01aa06 - granted - bimeda animal health limited - panchris feeds (veterinary) ltd
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - Πρόδρομη κυτταρική λεμφοβλαστική λευχαιμία-λέμφωμα - Αντινεοπλασματικοί παράγοντες - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.